Zomedica Corp. (AMEX: ZOM) is 51.78% higher than its annual trading volume so far and has hit the low $ 0.06 low and $ 0.50 high on the current 52-week trading list. ZOM’s stock was last seen floating around $ 0.23 in the last trading session, with daily profits setting up 0.12% of its average price target of $ 0.30 over the next 12 months. And -16.67% is a discounted high price of $ 0.30 offered by 1 analysts, but the current levels of 16.67% are lower than the low price of $ 0.30 at the same time.
Currently trading at $ 0.35, the stock is 82.05% and 152.70% higher than the SMA20 and SMA50 respectively. However, with a daily trading volume of 378.42 million and a change of 51.78% it currently leaves stock in its SMA200 of 129.43%. IZOM registered a profit of 5.39% per annum compared to a 6-month profit of 103.49%. The firm has an easy 50-day moving average (SMA 50) of $ 0.1748 and a 200-day easy-going (SMA200) average of $ 0.1386.
The stock saw 85.28% losses in the last 1 month and extending the period to 3 months gives it 264.96%, and an increase of 52.77% over the past 5 days. When we estimate the variance in stock prices during the week and month, we find that the exchange rates stand at 18.53% during the week and 11.77% over the month.
Forecasters of Zomedica Corp. Analysts (ZOM)
The analysts’ recommendations provided by FactSet indicate that the consensus forecast for Zomedica Corp. (ZOM) is “Buy”. The 1 analysts who offer their stock recommendations have an average rating of 2.00, of which 0 is rated as Hold and 0 is considered “Overweight”. 1 of the analysts rate the stock as “Buy”. 0 analysts rated stocks like Sell or Underperform.
IZomedica Corp. It is expected to release its quarterly report on 05/18/2021 and the quarterly salary per current quarterly budget is estimated at $ 0. EPS is expected to decrease by 4.50% this year.
Zomedica Corp. (ZOM) Analyst Forecasts
31 institutions hold shares in Zomedica Corp. (ZOM), with 24.93M shares held internally accounted for 4.42% while institutional investors held 6.62% of the company’s shares. The remaining shares are 550.54M, with the flat at 539.13M and Short Float at 8.02%. Institutions hold 6.33% of the Flat.
The main staff share of the company is Cambridge Investment Research Advisors Inc. with more than 12.25 million shares worth $ 1.35 million. Investor management represents 11.34% of the remaining ZOM shares. As of Sept. 29, 2020, the second largest owner is Vanguard Group, Inc. (The) with 10.78 million shares valued at $ 1.19 million to account for 9.97% of the remaining shares. Other top investors are Millennium Management LLC holding 2.87 million shares representing 2.66% and valued at more than $ 0.32 million, while Geode Capital Management, LLC owns 1.68% of the shares of 1.82 million with a market value of $ 0.2 million .
Zomedica Corp. (ZOM) Senior Management Officers
31 institutions hold shares in Zomedica Corp. (ZOM), with 24.93M shares held internally accounted for 4.42% while institutional investors held 6.62% of the company’s shares. The remaining shares are 550.54M, with the flat at 539.13M and Short Float at 8.02%. Institutions hold 6.33% of the Flat.
The main staff share of the company is Cambridge Investment Research Advisors Inc. with more than 12.25 million shares worth $ 1.35 million. Investor management represents 11.34% of the remaining ZOM shares. As of Sept. 29, 2020, the second largest owner is Vanguard Group, Inc. (The) with 10.78 million shares valued at $ 1.19 million to account for 9.97% of the remaining shares. Other top investors are Millennium Management LLC holding 2.87 million shares representing 2.66% and valued at more than $ 0.32 million, while Geode Capital Management, LLC owns 1.68% of the shares of 1.82 million with a market value of $ 0.2 million .
Zomedica Corp. (ZOM) Internal function
The latest transaction is in-house acquisition by POWERS JOHNNY D, Director of the company. The SEC’s indication shows that POWERS JOHNNY D bought 625,000 shares in the company’s regular stock exchange on July 07 for $ 0.16 per share totaling $ 100000.0. After the purchase, the insider now owns 0.63 million shares.
